Peptide Research, Industry Updates & Practical Guides

By What Peptides Editorial Team · Updated 2026-09-14 · Pillar guide

Peptide research reaches most readers in fragments: a screenshot of a laboratory certificate, a headline about an approval, a video demonstration of some procedure, a calculator that converts one unit into another. Each fragment carries numbers that look authoritative, and each usually arrives without the method, the population or the legal category that gives those numbers meaning. This hub is about reading the documents rather than repeating the numbers. It covers third-party analytical test reports, clinical trial abstracts, regulatory approval documents, the legal difference between a brand, a generic and a compounded preparation, official registers, adverse event grading, and the unit mistakes that turn an ordinary figure into a wrong one.

The scope here is method and reporting. This site publishes no dose for any person, no reconstitution procedure, no route of administration and no therapeutic or outcome claim. Tirzepatide, semaglutide and tesamorelin are prescription medicines in the jurisdictions where they are approved; retatrutide is described in the published literature as an investigational 39 residue triple agonist studied in phase 3 trials. Where a compound is still in clinical investigation, this page says so rather than implying otherwise. Nothing here is personal guidance, and nothing here should be read as a suggestion to start, stop or continue any medicine. For a decision about a named product, the two correct stops are your national regulator and a licensed clinician.

The cluster below is organized by document type. Reports attributed to independent laboratories, covered in how third-party peptide test reports are structured, sit alongside questions about video demonstrations of peptide handling. A second group is regulatory: what regulators have published about compounded tirzepatide and how approval and labelling news is reported. Each child page works through one document and states no amount for any person.

How Third-Party Analytical Testing of Peptide Materials Works

A certificate of analysis for a peptide batch is a summary, not a measurement. Behind it sit a handful of named methods, each answering one question and each blind to the others. Reversed phase high performance liquid chromatography separates the material on a hydrophobic column and reports purity as a percentage of detected peak area at a stated wavelength, commonly 214 nm or 220 nm where the peptide bond absorbs. Mass spectrometry, either coupled to the liquid chromatograph or run as MALDI-TOF, compares an observed mass with the theoretical mass calculated from the sequence. Karl Fischer titration reports residual water as a percentage by mass. The limulus amebocyte lysate test reports endotoxin in units per unit of mass or per container, and a sterility test reports growth or no growth under a named pharmacopoeial chapter. A reader who knows which question each method answers can tell what a report does not say.

Purity is the field most often over-read. An area percent measured at one wavelength says nothing about material that does not absorb at that wavelength, about co-eluting species hidden under the main peak, or about counter-ion and residual solvent. A peptide supplied as a trifluoroacetate salt carries counter-ion mass that is not peptide, so a vial filled to a stated mass of salt does not contain that mass of peptide. Net peptide content is a separate line from chromatographic purity, and laboratories differ on whether they subtract water and counter-ion before reporting it. Two reports can both be accurate and still differ by several percent because one reports peak area and the other reports corrected peptide content. Neither number, on its own, establishes identity or sterility.

Identity is a separate claim again. A single intact mass matches every isomer of the same composition, so leucine and isoleucine, which share a formula, cannot be separated by intact mass alone; tandem fragmentation and sequence coverage are what distinguish them. A report showing only a chromatogram with one peak has not established identity at all, only that one species dominated at one wavelength. Endotoxin and sterility results are likewise independent of purity: a very pure peptide can fail a bacterial endotoxin test, and a sterile one can be the wrong sequence. Material labelled research use only sits outside the medicine system entirely, and no amount of testing converts it into an approved medicine. The order in which a laboratory runs these assays and what each output looks like are set out in the analytical methods page.

Reading a Certificate and a Label: Units, Concentration and Total Content

Most unit errors are not arithmetic errors, they are category errors. A milligram and a microgram both measure mass, and the conversion between them is a factor of 1000. An international unit is different in kind: it measures biological activity against a reference standard, and the mass corresponding to one unit is set substance by substance by the body that maintains that standard, not by arithmetic. Where an international standard exists the conversion is published; where none exists, no conversion exists at all, and a label that states units without naming the standard leaves two products incomparable. The same trap appears with molar amounts. One milligram of a 4000 Da peptide corresponds to 0.25 micromol, so a concentration quoted in micromolar and a content quoted in milligrams describe the same vial in different currencies.

Concentration and total content are the second pair that gets confused. A concentration in mg per mL says nothing about how much a container holds until a volume is supplied, and a total content in mg says nothing about strength until a volume is supplied. Labels may state both, one, or a percentage, and a percentage needs its denominator: percent of label claim, percent of area, percent by mass. Fill mass, net peptide content and the peptide fraction of a salt are three further quantities that are quietly different. Growth hormone is a clean example of why mass alone is thin information: the 191 residue form has a mass near 22 kDa, and activity is defined against a standard rather than derived from that number. Two related pages stay with the units rather than the amounts: how the 191 amino acid growth hormone form is described and why published amounts are reported without a dose.

Calculators reproduce whatever units are typed into them, and they do not check the category. A tool that converts mg to mcg will also convert a concentration into a total content if the field is mislabeled, and the output carries the confidence of a number without the reasoning behind it. The check is to write the units into every line and cancel them: mg per mL multiplied by mL gives mg, and if the result still carries a per mL then a volume was never supplied. Pages on this site that discuss published amounts, including how a dosing line in a trial abstract is read and where calculator conversions go wrong, stay with the units and state no amount for any person.

• Units of mass versus units of activity: mg and mcg measure mass, IU measures activity against a reference standard, and the conversion differs by substance.
• Concentration versus total content: a label may state mg per mL, mg per container, or both, and only the total content tells you what the container holds.
• Salt form and counter-ion: a peptide shipped as a trifluoroacetate or acetate salt carries counter-ion mass that is not peptide.
• Net peptide content: purity percent applied to the filled mass, with residual water and counter-ion subtracted in some laboratories and not in others.
• Significant figures and rounding: 99.2 percent and 99.20 percent imply different analytical confidence.
• Lot or batch number: without one, a certificate cannot be tied to the specific vial in front of you.

How to Read a Clinical Trial Abstract

A trial abstract is a structured summary with fixed fields, and reading it in that order prevents most misreadings. The methods section states the design, the phase, whether allocation was randomized, who was blinded, the number of participants randomized, the inclusion criteria and the follow-up period. The results section reports the primary endpoint with an effect estimate and usually a 95 percent confidence interval, then secondary endpoints and safety counts. Phase 1 studies typically examine safety, tolerability and pharmacokinetics in small groups; phase 2 compares several amount levels and looks for signal in a few hundred participants; phase 3 compares against placebo or an active comparator in a larger population. Registration on a public registry such as ClinicalTrials.gov lets a reader check whether the endpoints reported are the ones that were prespecified.

The number that deserves the most scrutiny is the primary endpoint, because it is the one the study was powered to answer. If the primary endpoint was not met, secondary endpoints and subgroup findings are hypothesis generating rather than confirmatory, however they are framed in the conclusion. Effect estimates should be read with their interval: a difference of 8 percent with a 95 percent interval of 2 to 14 percent, and the same difference with an interval of minus 3 to 19 percent, are different findings. Absolute and relative figures are also different statements about the same data, and a report that gives only the relative figure hides the baseline it was calculated from. Withdrawals, loss to follow up and the analysis population, usually intention to treat, belong in the same reading.

Combination and comparator designs add a further layer. A trial of two antibodies given with or without a third agent is testing the contribution of each component, and the arms and endpoint hierarchy in the abstract are where that structure is visible; antibody combination trial design works through one such example. Sponsorship, funder and dates are disclosed fields and belong in the assessment, since the sponsor runs the analysis and holds the dataset. Full texts, protocols and posted results are indexed in public archives, and a finding that exists only as a press release should be treated as unverified until the registry record or the publication is located.

Reading an Approval Document and Checking an Official Register

An approval is a document, not a headline. In the United States the Food and Drug Administration publishes approval letters, summary reviews and product labeling as separate files; in the European Union the European Medicines Agency publishes a European public assessment report containing the scientific discussion behind the opinion. Both state the exact indication wording, the strengths and presentations, the marketing authorization holder, the manufacturing sites and any additional risk management measures. The indication wording is the part that matters most and the part usually paraphrased away: an authorization covers a named use in a named population under named conditions in one jurisdiction. A product approved in one country is not thereby approved in another, and one brand name can cover different formulations in different markets.

Verification means reproducing an entry from the regulator's own database rather than accepting a screenshot. National regulators maintain searchable lists of authorized medicines; the United States also maintains the Orange Book of approved drug products with therapeutic equivalence evaluations, and most countries publish an equivalent list with the holder's name attached. A pharmacy can be checked against the register of the board or authority that licenses it in its own country, and in the United States pharmacies compounding under section 503A and outsourcing facilities registered under section 503B sit under different arrangements. A registration number that cannot be reproduced from the regulator's own search page should be treated as unverified, and a product obtained outside the dispensing chain has no entry to find.

Compounding policy is the area that moves fastest, and it moves differently in each jurisdiction. Whether a named substance may be compounded, and under what conditions, is determined by national law and by the regulator's current position on shortages and on the legal source of the active ingredient. That is why this site reports status and points readers to the regulator rather than asserting a rule, and why every page here repeats the same two stops: check with your national regulator and speak to a licensed clinician. Reporting on what has actually been published for tirzepatide is collected in the regulatory news page and in the compounding page linked above.

• Find the medicine in the regulator's own database rather than on any seller's page.
• Match the name, strength, presentation and marketing authorization holder exactly, character by character.
• Check whether the dispensing pharmacy appears on the register of the board or regulator for its own country.
• Read the indication wording as written; an approval covers a specific use in a specific jurisdiction.
• Note the document date, because approvals, shortage lists and compounding policies change.
• Treat any registration number that cannot be reproduced from the regulator's search page as unverified.

Brand, Generic and Compounded: What Each Term Means Legally

Brand, generic and compounded are legal categories, not quality grades. A brand medicine is the innovator's product, authorized under a marketing application with a proprietary name, a defined strength, a defined presentation and a named holder. A generic contains the same active substance and is authorized through an abbreviated pathway on the basis of equivalence to a reference product, so the active moiety, strength and route are expected to match while excipients, device and packaging may not. A compounded preparation is different again: it is prepared by a pharmacy for an identified patient under pharmacy law, and in the United States compounded preparations are not approved by the Food and Drug Administration as products. That is a statement about the authorization pathway, not a claim about what is in the container.

The distinction shows up in what a label can carry. An authorized medicine carries the regulator's approved labeling, a patient information leaflet, an authorization number and the holder's name; the tirzepatide products authorized in several jurisdictions are held by eli lilly, and that name plus the authorization number is what a register search returns. A compounded preparation carries a pharmacy label with the dispensing pharmacy, a prescription reference and a beyond use date, and no regulator-reviewed patient leaflet, because none exists for it. An unapproved product sold as though it were a medicine carries none of these. Questions about which presentations exist, of the kind asked on the tirzepatide brand name page, are answered the same way, by checking what the register lists.

Formal equivalence also has limits worth naming. Therapeutic equivalence evaluations apply to an authorized generic relative to its reference product and say nothing about a preparation that never went through an application. For larger peptide and protein substances regulators use a comparability or biosimilar framework instead, because such a molecule is defined by its manufacturing process as much as by its sequence. A reader comparing two products should therefore compare category first, then naming, then holder, and only then the numbers on the label. Regulatory reporting on the authorized tirzepatide products and their holder is collected in the eli lilly tirzepatide page.

How Adverse Events Are Graded and Reported

Safety reporting in trials is a vocabulary with rules. Investigators record events, assign a standardized term from a dictionary such as MedDRA, and grade severity on the five point Common Terminology Criteria for Adverse Events scale, where grade 1 is mild, grade 2 moderate, grade 3 severe or medically significant but not immediately life threatening, grade 4 life threatening and grade 5 death related to the event. Trials report treatment emergent adverse events, serious adverse events, events leading to discontinuation and events of special interest separately, and each of those four counts answers a different question. A table reporting only discontinuations understates events that were managed, and a table reporting only common events can omit the serious ones entirely.

Lay vocabulary maps onto this system imperfectly. The phrase behind a query such as sulfur burps describes a set of gastrointestinal sensations; the terms a trial publication would use for the same territory include dyspepsia, eructation, flatulence and gastrointestinal disorder, each recorded as a preferred term and graded. Reporting of this kind does not assert that the medicine caused the event, and an incidence printed in a publication is a count within that study population under that protocol, not a general rate. The page on gastrointestinal adverse event terminology stays with the vocabulary and the grading. Anyone experiencing symptoms while taking a prescribed medicine should speak to a licensed clinician and should not start, stop or change anything on the basis of a published table.

After approval, reporting continues through pharmacovigilance. National systems collect spontaneous reports from clinicians, manufacturers and patients; the United States maintains FAERS, the European Medicines Agency maintains EudraVigilance and the World Health Organization maintains VigiBase, and each is a case series without a denominator. A count in a spontaneous database reflects how many reports were submitted, not how many people were exposed, so it cannot be converted into an incidence. These systems are useful for signal detection, which is what they are built for, and regulators say so explicitly in their documentation. Reading them as rates is one of the more common errors in health reporting, and it is worth unlearning before reading any of them.

Judging an Online Tutorial, and Where to Go Next

A tutorial is credible in proportion to the checks it makes visible. Named authorship with a stated qualification, a date, links to the primary sources being described, an explicit statement of what the material is and is not licensed for, and a separation between demonstration and instruction are all observable features, and the absence of any of them is equally observable. A video can show a sequence of actions but cannot show identity, purity, endotoxin or sterility, and a demonstration performed on a bench is not performed under the conditions a pharmacopoeia requires. Demonstrations of handling are treated on this site as a documentation question, which is how the page on retatrutide handling videos and its neighbours handle them: no volumes, no procedure, no route of administration, no amount stated for any person.

Commercial interest is the second filter. A page that describes a material and then sells it, a page whose only sources are other pages selling the same material, and a page that quotes a study while omitting its population and endpoint are all making the same structural choice. Regulator and registry sources sit outside that structure because they are records rather than arguments. Where a claim is specific, the check is short: find the registry record or the approval document and confirm the number appears there. Where a claim cannot be traced to either, it is not a fact, and where a page carries no date its status statements are already stale.

The other four hubs on this site handle the questions this one does not. Structure, bonding, residue mass and classification are covered in the peptide science hub, which is the place to start when a word on a certificate is unfamiliar. Cosmetic labeling, INCI order and what a topical product can be checked for belong to the cosmetic peptides hub. How supplier quality claims are assessed from public documents, with no ranking and no endorsement, is set out in the supplier quality hub. Composition, supplement categories and third-party testing marks are covered in the peptide wellness hub. None of them gives personal guidance, and none of them sells anything.

• A named author with a stated qualification and a date visible on the page.
• Primary sources linked: a registry record, an approval document, or the journal itself.
• Method detail present, meaning the wavelength, gradient, standard or population behind each number.
• The legal category stated, so a prescription medicine, a supplement and a research material are not discussed as one thing.
• Limits stated rather than omitted, including what the reported method cannot detect.
• No commercial interest in the conclusion, or that interest disclosed plainly near the claim.